Topic Hub
9 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 9 of 9 clinical reviews.
Evidence-based guide to lisdexamfetamine dosing considerations for East Asian patients, covering CYP2D6 pharmacogenomics, body-weight corrections, and clinical monitoring.
Read clinical reviewA clinical review of how Vyvanse (lisdexamfetamine) may differ in safety, dosing, and cardiovascular risk for patients of Black or African ancestry, with pharmacogenomic context and evidence-based guidance.
Read clinical reviewA clinician-reviewed guide to how lisdexamfetamine (Vyvanse) behaves differently in East Asian patients, covering CYP2D6/CYP2C19 genetics, BMI-adjusted dosing thresholds, cardiovascular monitoring, and ethnicity-stratified trial data.
Read clinical reviewA clinical deep-dive into how ethnicity-linked pharmacogenomics, diabetes prevalence, and cardiovascular risk shape the safety profile of lisdexamfetamine (Vyvanse) in Hispanic and Latino patients, with dosing guidance and monitoring recommendations.
Read clinical reviewA clinical review of lisdexamfetamine (Vyvanse) efficacy data in Black and African ancestry patients, covering pharmacogenomic differences, ethnicity-stratified trial subgroups, cardiovascular monitoring, and dosing considerations.
Read clinical reviewA clinical deep-dive into lisdexamfetamine (Vyvanse) efficacy in Hispanic and Latino patients, covering pharmacogenomic variants, ethnicity-stratified trial subgroups, and practical dosing guidance reviewed by board-certified physicians.
Read clinical reviewEvidence-based review of how lisdexamfetamine (Vyvanse) efficacy and metabolism differ in South Asian populations, including pharmacogenomic factors, dosing considerations, and cardiovascular risk context.
Read clinical reviewHow South Asian genetics, cardiovascular risk thresholds, and CYP2D6 polymorphisms affect lisdexamfetamine (Vyvanse) safety, dosing, and monitoring.
Read clinical reviewA clinical guide to lisdexamfetamine (Vyvanse) dosing in South Asian patients, covering pharmacogenomics, cardiovascular risk at lower BMI, CYP enzyme variants, and evidence-based titration strategies.
Read clinical review